🚀 Dreaming of a career where you can make a difference? Discover the endless possibilities at NIAID with our #recruitment video. Whether you’re passionate about science, administration, or innovation, there is a place for you. Learn more from some of the dedicated public servants who make NIAID a great place to work: https://lnkd.in/e-sD2kX5 #PSRW #NIAIDCareers
National Institute of Allergy and Infectious Diseases (NIAID)
Government Administration
Rockville, Maryland 43,529 followers
Join NIAID and make a difference!
About us
This is the official LinkedIn account for the National Institute of Allergy and Infectious Diseases (NIAID). NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. Posted comments and images do not necessarily represent the views of NIAID, NIH. Comment Policy: www.niaid.nih.gov/global/comment-policy Privacy Policy: www.niaid.nih.gov/privacy Website: www.niaid.nih.gov
- Website
-
http://www.niaid.nih.gov
External link for National Institute of Allergy and Infectious Diseases (NIAID)
- Industry
- Government Administration
- Company size
- 1,001-5,000 employees
- Headquarters
- Rockville, Maryland
- Type
- Government Agency
Locations
-
Primary
9500 Rockville Pike
Rockville, Maryland 20892, US
Employees at National Institute of Allergy and Infectious Diseases (NIAID)
-
Gail Potter
Deputy Section Chief, Clinical Trials Research Section, at National Institute of Allergy and Infectious Diseases (NIAID)
-
Rodolfo Alarcon
Program Officer at National Institutes of Health/National Institute of Allergy and Infectious Diseases
-
Dave Chen
Senior Visualization Scientist at National Institute of Allergy and Infectious Diseases (NIAID)
-
Michael Mullins
Updates
-
Viral #hepatitis affects the lives of about one in twenty people in the world, resulting in over a million deaths each year. NIAID is working on many ways to prevent and treat the different types of hepatitis, including the development of vaccines and improved therapeutics and diagnostics. July 28 is observed annually as #WorldHepatitisDay, providing an opportunity to reflect on the impact of hepatitis on global health and focus on strategies to reduce its burden. To observe World Hepatitis Day, NIAID highlights recent advances researchers have made in these areas. Learn more at https://go.nih.gov/UpN6IiI
-
VIDEO: Check out the #NIAID blog for the latest updates from #AIDS2024 covering long-acting injectables, bi-directional learning, PACHA & more. Learn more: https://go.nih.gov/qlqsEpW Photo credit: HIVgov
-
National Institute of Allergy and Infectious Diseases (NIAID) reposted this
NIH’s approach to test therapeutic interventions for Long COVID is evolving. We will apply lessons learned from NIH Researching COVID to Enhance Recovery (RECOVER) studies and trials to develop a new program called RECOVER-Treating Long COVID (RECOVER-TLC). RECOVER-TLC will call upon the research community to help identify promising therapeutic approaches and study designs that will produce results that are needed by those affected by Long COVID. We need input from the research and Long COVID communities to ensure RECOVER-TLC can be a success. A kick-off meeting will be held September 23-25. Check back to this page for registration updates: https://lnkd.in/g4V4cUfT #LongCOVID #NIHRECOVER
-
Day 5 of #AIDS2024 #NIAID science snapshot for Friday, July 26: - Ensitrelvir showed antiviral activity, safety, & reduced time to #COVID19 symptom resolution in non-hospitalized adults but fared little better than placebo in time needed to fully resolve symptoms. - A #COVID19 vaccine study found people living with #HIV had high exposure to tuberculosis. The results demonstrate the need for #TB screening, surveillance, & collaboration with health experts for comprehensive HIV and TB care. - A study found that the bivalent #COVID19 #vaccine mRNA-1273 provided no additional protection compared to the monovalent vaccine for people living with or without #HIV when #Omicron variants were evolving. For full text abstracts, visit the AIDS 2024 program: https://lnkd.in/dfH9MuVC #vaccines
-
#NIAID-supported scientists have identified small molecules that trigger #TrainedImmunity, a form of innate immune-system memory, without a pathogen or host molecule activating innate immunity first. These newly identified compounds surprisingly include steroids, which are usually #immunosuppressive. Also, unlike the few previously identified molecules that trigger trained immunity, the new ones are easy to make and deliver, the scientists say. These findings could help researchers develop new or improved vaccines and treatments. Learn more: https://lnkd.in/eD-3YJ7M #NIH #immunology #science #research Pritzker School of Molecular Engineering at the University of Chicago Image credit: PubChem
-
National Institute of Allergy and Infectious Diseases (NIAID) reposted this
NIH is taking steps to re-envision the postdoctoral training experience, but the feedback of the biomedical research community is a crucial part of this process. Among the actions under consideration are: ➡️Limiting the amount of time a postdoctoral scholar can be supported by NIH funds to five years to speed transition into research careers. ➡️ Shorten the eligibility window and refocus review criteria for a key mentored career development award (K99/R00) to facilitate more rapid transition of postdoctoral scholars. ➡️Enhancing training and professional development for postdoctoral scholars and their mentors. Share your feedback by October 23, 2024: https://go.nih.gov/amqQ7DD
-
VIDEO: Check out the #NIAID blog for the latest updates from #AIDS2024 covering #NIH research updates, HIV criminalization laws, and AI. Learn more: https://go.nih.gov/0lZ6C8e Image credit: HIVgov
-
Day 4 of #AIDS2024 #NIAID science snapshot for Thursday, July 25: - A multicenter study found long-acting cabotegravir (CAB-LA) combined with rilpivirine (RPV) was safe and acceptable antiretroviral therapy in adolescents with suppressed #HIV who switched from daily oral CAB-LA RPV. - An analysis from a large study of long-acting cabotegravir for #HIV pre-exposure prophylaxis showed drug concentrations decreased over the course of pregnancy, but still remained above the levels associated with HIV prevention efficacy. - A study found young adults with perinatally acquired #HIV whose virus was not fully suppressed by treatment had increased biomarkers of cardiovascular disease, and those with metabolic syndrome had increased inflammatory biomarkers. - Symptoms of depression, anxiety, and PTSD were present among people with #HIV over the age of 40 years in countries with lower & middle incomes. This discovery shows the need for pathways to improved mental health in these populations. For full text abstracts, visit the AIDS 2024 program: https://lnkd.in/dfH9MuVC
Conference Programme
programme.aids2024.org
-
#NIAID seeks a highly qualified candidate to serve as Scientific Diversity Officer (Associate Director for Scientific Research Strategy): Develop and implement a strategy to better address health disparities and health equity in allergy, immunology, and infectious diseases research while simultaneously establishing a broadly representative scientific career development pipeline of trainees and investigators. Applications open 8/11/24. Learn more at https://go.nih.gov/dta45Ix #NIAIDCareers
Scientific Diversity Officer (Associate Director for Scientific Research Strategy)
niaid.nih.gov